This news story describes how data from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) show that more than 200 deaths are suspected of being linked to popular weight-loss injections. More than 150,000 adverse reactions have also been reported. The figures cover several of the drugs, including Mounjaro (tirzepatide), Wegovy and Ozempic (semaglutide), and Saxenda (liraglutide).
Tirzepatide, sold as Mounjaro, accounted for 120 reported deaths and more than 106,000 adverse reactions. Semaglutide, the active ingredient in Wegovy and Ozempic, was associated with 59 reported deaths and more than 48,000 adverse reactions. Liraglutide, sold as Saxenda, was linked to 37 deaths and more than 4,400 adverse reactions.
The use of these injectable drugs is growing rapidly in the UK. An analysis by University College London estimated that around 1.6 million people in Great Britain had used weight-loss medications between early 2024 and early 2025, while a further 3.3 million were apparently planning on using them.
To learn the facts about the weight-loss industry that the mainstream/legacy media isn’t reporting, see this article by Dr. Aleksandra Niedzwiecki on our website.
Congo Says 2,000 People Have Died in History’s Fastest-Growing Ebola Outbreak
August 21, 2026Bribery, Kickbacks, and Fake Research: Study Exposes the Dark Side of Pharma
August 21, 2026More Than 200 Deaths with Suspected Links to Weight Loss Injections Reported to UK Health Officials
News
More than 200 reports from people who suspect deaths were related to ingredients contained in weight loss jabs like Wegovy and Mounjaro have been made to UK health officials, according to new figures.
[Source: mirror.co.uk]
[Image source: magnific.com]
Comment
This news story describes how data from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) show that more than 200 deaths are suspected of being linked to popular weight-loss injections. More than 150,000 adverse reactions have also been reported. The figures cover several of the drugs, including Mounjaro (tirzepatide), Wegovy and Ozempic (semaglutide), and Saxenda (liraglutide).
Tirzepatide, sold as Mounjaro, accounted for 120 reported deaths and more than 106,000 adverse reactions. Semaglutide, the active ingredient in Wegovy and Ozempic, was associated with 59 reported deaths and more than 48,000 adverse reactions. Liraglutide, sold as Saxenda, was linked to 37 deaths and more than 4,400 adverse reactions.
The use of these injectable drugs is growing rapidly in the UK. An analysis by University College London estimated that around 1.6 million people in Great Britain had used weight-loss medications between early 2024 and early 2025, while a further 3.3 million were apparently planning on using them.
To learn the facts about the weight-loss industry that the mainstream/legacy media isn’t reporting, see this article by Dr. Aleksandra Niedzwiecki on our website.
Dr. Rath Health Foundation
Related posts
Probiotic Supplement Attenuates Exercise-Induced Muscle Damage After Just Four Weeks
Read more